The three IL-17 inhibitors have been shown to be effective in Phase 3 of the clinical trials in the treatment of moderate forms of psoriatic plaque, psoriatic arthritis, and AS [66,67], but have been associated with worsening of IBD, especially Crohn’s disease with placebo [68]. Here, IL17A is linked to inflammatory bowel disease.